Form 4: BioLife Solutions Executive Sells Shares Under 10b5-1 Plan

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 349 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Todd Berard, the Chief Marketing Officer of BioLife Solutions, sold 349 shares of the company's common stock on November 26, 2024.
• The shares were sold at a price of $27.2 per share.
• This transaction was executed under a pre-existing Rule 10b5-1 trading plan.
• The trading plan was adopted on February 24, 2022.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock.
• Following the transaction, Berard directly owns 107,407 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing for insider transactions and is common for executives who have pre-arranged trading plans to manage their stock holdings and tax obligations.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate executives to avoid accusations of insider trading.
• The sale of shares by an executive is a normal occurrence and does not necessarily indicate a negative outlook for the company.
• Similar filings are regularly made by executives at comparable companies such as Cryoport and Thermo Fisher Scientific.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or long-term prospects.

Key Dates

Keywords

BioLife Solutions, BLFS, Todd Berard, insider trading, Form 4, 10b5-1 plan, stock sale, executive transaction, share sale